The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.
 
Praful Ravi
No Relationships to Disclose
 
Neil E. Martin
No Relationships to Disclose
 
Quoc-Dien Trinh
Honoraria - Astellas Pharma; Bayer; Janssen
Research Funding - Intuitive Surgical
 
Grace Shaw
No Relationships to Disclose
 
Mark Pomerantz
Honoraria - Bayer
 
Mark A. Preston
No Relationships to Disclose
 
Manuel Pedregal
No Relationships to Disclose
 
Mary-Ellen Taplin
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Pfizer; Progenics; Research to Practice; UpToDate
Consulting or Advisory Role - AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Adam S. Kibel
Honoraria - InSightec; Janssen; Merck; profound
Consulting or Advisory Role - Bristol-Myers Squibb
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination